In 2017, Carlos Ciller, Stefanos Apostolopoulos, and Sandro De Zanet founded RetinAI with a clear vision: to transform how healthcare professionals make decisions about eye disease. Their journey began with a simple but powerful insight - the wealth of medical imaging and clinical data being generated daily was too fragmented and complex to unlock its full potential for patient care. By developing RetinAI Discovery, an AI-powered platform that harmonizes and analyzes multimodal data at scale, the founders created a bridge between raw data and actionable medical insights.
Today, RetinAI serves pharmaceutical companies, clinical researchers, and healthcare providers globally, enabling faster drug development, optimized clinical trials, and improved patient outcomes. The platform's certified AI models analyze optical coherence tomography, fundus photography, and other ophthalmic imaging to detect biomarkers associated with conditions like age-related macular degeneration, diabetic retinopathy, and glaucoma. With FDA clearance and CE Marking as a Class IIa medical device, RetinAI has established itself as a trusted partner in the quest to enable the right decisions sooner in healthcare.
